Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens — aspirin plus extended-release dipyridamole (ASA ...
9/18/2008 · Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens — aspirin plus extendedrelease dipyridamole (ASA–ERDP) versus clopidogrel. In this double-blind, 2-by-2 …
The study was sponsored by the maker of the aspirin/dipyridamole combination (Aggrenox). ... incidence of major hemorrhage with aspirin/dipyridamole compared with clopidogrel (4.1% vs. 3.6%) was ...
Aspirin and Extended-Release Dipyridamole vs. Clopidogrel for recurrent Stroke n engl j med 359;12 www.nejm.org september 18, 2008 1239 R ecurrent stroke is an important
Aggrenox is a combination of extended-release dipyridamole and aspirin; it was superior to aspirin alone in the second European Stroke Prevention Study (Diener et al, 1996). Multiple randomized clinical trials have examined antiplatelet agents in prevention of vascular events, but no study has compared clopidogrel to dipyridamole plus aspirin.
Aggrenox (Aspirin / Dipyridamole) prevents blood clots and stroke, but cheaper options are available that work just as well. Plavix (clopidogrel) is a cheap, generically available blood thinner that protects you from clots after you've had a heart attack or surgery.
Dutch TIA Trial Study Group, van Gijn J, Algra A, et al. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325:1261. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis.
7/1/2012 · Plavix (clopidogrel) Plavix (clopidogrel) has solid data. Aggrenox has 0ne study with many flaws. Pts with strokes also tend to have cardiovascular and peripheral disease. Plaxix reduces mortality in these pts and Aggrenox doesnt. Plavix (clopidogrel) is now generic and Aggrenox is expensive.
5/28/2014 · Patient was prescribed Aggrenox for stroke prophylaxis. However, the medication was not covered by the patient's insurance. Find an alternative medication- both aspirin and Plavix are covered by the patient's insurance. Therapy Choices Five antiplatelets are approved by the FDA for secondary stroke prevention: Aspirin Clopidogrel (Plavix) Ticlopidine (Ticlid) Dipyridamole/ASA (Aggrenox ...
The AMBulatory Dual Anti-Platelet (AMBDAP) study was designed to determine whether dual antiplatelet therapy with aspirin and clopidogrel was more effective than therapy with aspirin and dipyridamole in preventing embolization in patients with acute symptomatic carotid stenosis. The primary end point was ES frequency measured using ambulatory TCD.
Aspirin Plus Dipyridamole Versus Clopidogrel . The PRoFESS study was designed as a noninferiority trial to test the efficacy of aspirin-EDRP against clopidogrel for stroke prevention. In a factorial design, 20,332 patients with prior stroke were enrolled.
8/12/2012 · Depends. Studies have been done comparing the two. Aggrenox seems superior in preventing recurrent stroke or tia's, but Plavix (clopidogrel) has more research on heart disease and periph vasc problems. Plavix (clopidogrel) is generic now and cheaper, but doesn't work well in pts with certain genetics, and interacts adversely with some ulcer drugs.
Studies have been done to compare the effectiveness of palvix versus Aggrenox in prevention of strokes. The results show that the outcomes are similar with both the medications. But there was higher incidence of bleeding tendency and headaches with Aggrenox when compared to Plavix.
Request PDF on ResearchGate | On Jan 31, 2009, Sacco RL and others published Aspirin and Extended-Release Dipyridamole vs. Clopidogrel for Recurrent Stroke
11/1/2018 · Table 1 Incidence of Adverse Events in ESPS2 a; a Reported by ≥1%/year of patients during Aggrenox treatment where the incidence was at least 1%/year greater than in those treated with placebo. b Annual event rate per 100 pt-years = 100* number of subjects with event/subject-years. Subject-years is defined as cumulative number of days on treatment divided by 365.25.
Indications and Usage Aggrenox ... † European Stroke Prevention Study 2 (ESPS 2): A randomized, double-blind, ... trial in which 20,332 patients were randomized to 25 mg of aspirin plus 200 mg of ER-DP twice daily or to 75 mg of clopidogrel once daily over a mean duration of 2.5 years.
The Japanese Aggrenox (Extended-Release Dipyridamole plus Aspirin) Stroke Prevention versus Aspirin Programme (JASAP) Study: A Randomized, Double-Blind, Controlled Trial
NIH study also shows that overall stroke risk is down from 10 years ago. Aspirin combined with the antiplatelet drug clopidogrel is no better than aspirin alone for stroke prevention in people with a history of lacunar strokes, and the combination carries a greater risk of gastrointestinal bleeding ...
Clopidogrel bisulfate is an anti-platelet drug, that is, a drug that inhibits the ability of platelets to clump together as part of a blood clot.Clopidogrel prevents blood clots by irreversibly binding to the P2Y12 receptor on platelets, preventing adenosine diphosphate (ADP) from activating platelets. It belongs to a class of drugs called P2Y12 inhibitors.
10/22/2018 · Clopidogrel is used to lower your risk of having a stroke, blood clot, or serious heart problem after you've had a heart attack, severe chest pain (), or circulation problems.. Clopidogrel may also be used for purposes not listed in this medication guide.
Plavix (clopidogrel) is a cheap, generically available blood thinner that protects you from clots after you've had a heart attack or surgery. Ecotrin (aspirin) can be used for pain and fever relief or heart protection, and is generally very safe and affordable.